Product logins

Find logins to all Clarivate products below.


Trauma Devices – Market Insights – Asia Pacific (Supplemental)

Growth in the Asia Pacific trauma device market will be supported by favorable demographics and rising adoption of innovative devices. However, several factors will dampen growth, such as the Chinese government’s volume-based procurement policy, which is placing downward pressure on ASPs in the country. In general, downward pricing pressures in various trauma device segments will partially offset the positive impact of procedure expansion and unit sales on revenues.

This Medtech 360 Report provides high-level market metrics for trauma devices in the Asia pacific region, including country-level data for major countries and aggregate data for the rest of the Asia pacific region from 2019 through 2033.

Table of contents


Related Medtech Insights Reports

Report
Peripheral Vascular Devices – Market Insights – United States
The US PV device market will be primarily driven by product innovation, novel technologies, and adoption of premium solutions. However, barriers such as the push for cost-effective PV interventions…
Report
Trauma Devices – Market Insights – United States
Long-term growth of the US trauma device market will be driven by the uptake of novel technologies such as 3-D printed implants, the expansion of the foot and ankle device segment, site-of-service…
Report
Peripheral Vascular Devices – Market Insights – Europe
The European PV device market will be mainly driven by the increasing availability of premium-priced products and emerging products which, supported by clinical data, will increase the penetration…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Japan
The Japanese EP mapping and ablation device market will experience moderate growth through 2034, supported by rising cardiac arrhythmia prevalence, broader treatment accessibility, and ongoing…
Report
Interventional Oncology Devices – Market Insights – United States
The US market for interventional oncology devices will be driven by the launch and uptake of higher-priced technologies, favorable clinical data, expanding populations that are treatable with…